Login
$RCAT
$4.87 +$0.47 (10.68%) Close

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q3 FY2024
As of Oct 31, 2024
Q2 FY2024
As of Jul 31, 2024
Q1 FY2024
As of Apr 30, 2024
Q4 FY2023
As of Jan 31, 2024
Q3 FY2023
As of Oct 31, 2023
Q2 FY2023
As of Jul 31, 2023
Q1 FY2023
As of Apr 30, 2023
Q4 FY2022
As of Jan 31, 2023
Q3 FY2022
As of Oct 31, 2022
Q2 FY2022
As of Jul 31, 2022
Q1 FY2022
As of Apr 30, 2022
Q4 FY2021
As of Jan 31, 2022
Q3 FY2021
As of Oct 31, 2021
Q2 FY2021
As of Jul 31, 2021
ASSETS
Current assets
Cash
Marketable securities
Accounts receivable, net
Inventory
Other
Current assets of discontinued operations
Prepaid expenses and other
Prepaid inventory
Prepaid expenses and other current assets
Total current assets
Goodwill
Intangible assets, net
Equity method investee
Note receivable
Property and equipment, net
Other long-term assets
Operating lease right-of-use assets
Long-term assets of discontinued operations
Total long-term assets
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable
Accrued expenses
Debt obligations - short-term
Contract liabilities and deposits
Operating lease liabilities
Warrant derivative liability
Current liabilities of discontinued operations
Convertible notes payable - short term
Acquisition consideration payable
Convertible notes payable
Total current liabilities
Deferred income taxes
Operating lease liabilities
Debt obligations - long term
Long-term liabilities of discontinued operations
Convertible notes payable - long term
Acquisition consideration payable
Total long-term liabilities
Total liabilities
Stockholders’ equity
Series B preferred stock - shares authorized 4,300,000; issued and outstanding 4,676 and 4,676
Series B preferred stock, $0.001 par value - shares authorized 4,300,000; issued and outstanding 4,676 and 4,676
Common stock, $0.001 par value - shares authorized 500,000,000; issued and outstanding 120,070,244 and 85,215,136
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Total stockholders’ equity
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support